Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,253,472

191 payments

Through program year 2025, Boston Clinical Trials is reported as receiving $1,253,472 in research payments, across 191 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $358,303 58
2024 Research $357,494 43
2023 Research $221,153 47
2022 Research $25,221 6
2021 Research $150,300 20
2020 Research $140,532 15
2019 Research $469 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $295,735 3 payments
  2. Sage Therapeutics, Inc. $293,882 6 payments
  3. Janssen Research & Development, LLC $115,143 18 payments
  4. Biogen, Inc. $112,407 1 payment
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $102,818 3 payments
  6. Biohaven Pharmaceuticals, Inc. $89,421 15 payments
  7. Boehringer Ingelheim International GmbH $86,794 52 payments
  8. H. Lundbeck A S $67,446 2 payments
  9. Merck Sharp & Dohme Corporation $55,216 3 payments
  10. AbbVie, Inc. $16,479 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study to Evaluate SAGE-324 in Participants With Essential Tremors $204,806 3 payments
  2. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $195,099 1 payment
  3. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $112,407 1 payment
  4. PoCC study in patients with PTSD $110,378 6 payments
  5. A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor $89,077 3 payments
  6. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $85,009 14 payments
  7. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $77,907 1 payment
  8. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $68,413 11 payments
  9. Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $67,446 2 payments
  10. Phase II DRF study of NR2B modulation in MDD $62,469 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record